Stage IIIA Non-Small Cell Lung Cancer: Morbidity and Mortality of Three Distinct Multimodality Regimens

被引:20
作者
Seder, Christopher W.
Allen, Mark S.
Cassivi, Stephen D.
Deschamps, Claude
Nichols, Francis C.
Olivier, Kenneth R.
Shen, K. Robert
Wigle, Dennis A.
机构
[1] Mayo Clin, Div Gen Thorac Surg, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Radiat Oncol, Rochester, MN 55905 USA
关键词
SURGICAL RESECTION; INDUCTION CHEMORADIATION; CHEMOTHERAPY; CARCINOMA; RADIATION; THERAPY; RADIOTHERAPY; SURVIVAL; SUPERIOR;
D O I
10.1016/j.athoracsur.2013.02.041
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Although concurrent chemoradiation therapy can cure stage IIIA non-small cell lung cancer (NSCLC), studies have demonstrated that anatomic resection following high-dose or standard-dose chemoradiation may benefit selected patients. We examined morbidity and mortality associated with 3 multimodality treatment regimens for stage IIIA disease. Methods. Institutional databases identified patients with stage IIIA (N2) NSCLC who underwent concurrent platinum-based chemoradiotherapy with or without pulmonary resection between 1998 and 2011. Exclusion criteria included palliative regimens, sequential chemoradiotherapy, radiation-surgery interval greater than 12 weeks, superior sulcus tumors, or radiotherapy other than standard external beam radiation. Treatment-related morbidity and mortality were examined for the following treatment regimens: neoadjuvant chemoradiotherapy with 45 Gy followed by surgery (trimodality-45); neoadjuvant chemoradiotherapy with 60 Gy or more followed by surgery (trimodality-60); and definitive chemoradiotherapy with 60 Gy or more without surgery (D-CRT). Results. During the study period, 144 patients met eligibility criteria including 27 trimodality-45, 29 trimodality-60, and 88 D-CRT patients. Treatmentrelated morbidity and mortality rates for D-CRT were 74% [65 of 88] and 2.3% [2 of 88], respectively. Postoperative morbidity and mortality rates for patients who proceeded to surgery were 48% [27 of 56] and 1.8% [1 of 56], respectively, and did not differ based on dose of neoadjuvant radiation. Despite varied anatomic resections and methods of bronchial closure and coverage, no bronchopleural fistulae were observed. Conclusions. Chemoradiotherapy carries a significant morbidity profile. However, high-dose neoadjuvant radiation is not associated with increased postoperative morbidity or mortality relative to standard-dose radiation in patients selected for anatomic resection. (C) 2013 by The Society of Thoracic Surgeons
引用
收藏
页码:1708 / 1716
页数:9
相关论文
共 23 条
[1]   Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J].
Albain, Kathy S. ;
Swann, R. Suzanne ;
Rusch, Valerie W. ;
Turrisi, Andrew T., III ;
Shepherd, Frances A. ;
Smith, Colum ;
Chen, Yuhchyau ;
Livingston, Robert B. ;
Feins, Richard H. ;
Gandara, David R. ;
Fry, Willard A. ;
Darling, Gail ;
Johnson, David H. ;
Green, Mark R. ;
Miller, Robert C. ;
Ley, Joanne ;
Sause, Willliam T. ;
Cox, James D. .
LANCET, 2009, 374 (9687) :379-386
[2]   CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].
ALBAIN, KS ;
RUSCH, VW ;
CROWLEY, JJ ;
RICE, TW ;
TURRISI, AT ;
WEICK, JK ;
LONCHYNA, VA ;
PRESANT, CA ;
MCKENNA, RJ ;
GANDARA, DR ;
FOSMIRE, H ;
TAYLOR, SA ;
STELZER, KJ ;
BEASLEY, KR ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892
[3]  
[Anonymous], 2013, NCCN GUID VERS 2
[4]  
[Anonymous], 2010, SURV EP END RES US N
[5]   Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival [J].
Bueno, R ;
Richards, WG ;
Swanson, SJ ;
Jaklitsch, MT ;
Lukanich, JM ;
Mentzer, SJ ;
Sugarbaker, DJ .
ANNALS OF THORACIC SURGERY, 2000, 70 (06) :1826-1831
[6]   Pulmonary resection after concurrent chemotherapy and high dose (60 Gy) radiation for non-small cell lung cancer is safe and may provide increased survival [J].
Cerfolio, Robert James ;
Bryant, Ayesha S. ;
Jones, Virginia L. ;
Cerfolio, Robert Michael .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 35 (04) :718-723
[7]  
CHOI NCH, 1981, CANCER-AM CANCER SOC, V48, P101, DOI 10.1002/1097-0142(19810701)48:1<101::AID-CNCR2820480120>3.0.CO
[8]  
2-S
[9]   POSTOPERATIVE COMPLICATIONS AFTER COMBINED NEOADJUVANT TREATMENT OF LUNG-CANCER [J].
FOWLER, WC ;
LANGER, CJ ;
CURRAN, WJ ;
KELLER, SM .
ANNALS OF THORACIC SURGERY, 1993, 55 (04) :986-989
[10]   Bronchial Stump Dehiscence: Update on Prevention and Management [J].
Liberman, Moishe ;
Cassivi, Stephen D. .
SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2007, 19 (04) :366-373